Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy

15. září 2026 aktualizováno: Mabwell (Shanghai) Bioscience Co., Ltd.

A Phase III, Open-label, Randomized-controlled, Multi-center Study of 7MW3711 Compared With Docetaxel in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy and Immunotherapy

To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .

Přehled studie

Postavení

Zatím nenabíráme

Detailní popis

A Phase III, Open-label, Randomized-controlled, Multi-center Study to Evaluate the Safety and Efficacy of 7MW3711 Compared with Docetaxel in Patients with Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy and Immunotherapy.

Typ studie

Intervenční

Zápis (Odhadovaný)

600

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Čína, 200043
        • Shanghai Chest Hospital
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 85 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • All trial participants or their legally acceptable representatives must sign the Ethics Committee-approved informed consent form before any screening procedures are initiated.
  • Aged 18 to 85 years (inclusive) at the time of signing the informed consent, regardless of gender.
  • ECOG performance status of 0 to 1.
  • Histologically or cytologically confirmed unresectable locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). Mixed pathology including small cell lung cancer or other pathological components must be excluded.
  • Must have received prior first-line systemic anti-tumor therapy, including: a) platinum-based doublet chemotherapy; b) immunotherapy (including but not limited to monoclonal antibodies targeting PD-1, PD-L1, CTLA-4, or their bispecific antibodies).
  • Radiologically confirmed disease progression during or within 6 months after discontinuation of the most recent treatment regimen.
  • Archived tumor tissue samples must be provided.
  • Expected survival of ≥ 3 months.
  • At least one measurable lesion per RECIST v1.1 criteria at screening. For those with a clear history of radiotherapy, measurable lesions must be outside the radiation field or have shown clear progression after completion of radiotherapy.
  • Organ function of trial participants must meet certain criteria.
  • Subjects with reproductive potential must take effective contraceptive measures during the trial and for 180 days after the last dose. Female subjects must be confirmed non-pregnant before enrollment, and lactating females must stop breastfeeding, unless surgically sterilized, postmenopausal, or without reproductive potential.
  • Able to understand and comply with planned visits, treatment, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Received radiotherapy, chemotherapy, or other anti-tumor treatments within 21 days before the first dose; received anti-tumor traditional Chinese medicine within 7 days; received other investigational drugs or devices not yet on the market within 28 days; previously received antibody-drug conjugates (ADCs) or docetaxel.
  • Positive for clinically significant driver gene mutations, including EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, HER2.
  • Persistent clinically significant toxicities of Grade ≥ 2 related to prior therapy (excluding alopecia and Grade 2 immune-related endocrine toxicities requiring stable doses of replacement therapy).
  • Trial participants with clinically symptomatic effusions requiring local therapy or repeated drainage (pleural effusion, ascites, pericardial effusion, etc.).
  • Underwent major surgery within 28 days before the first dose of study drug, excluding minor surgeries judged by the investigator as not affecting participation in the trial.
  • Received live vaccines within 28 days before the first dose of study drug, or plan to receive any live vaccines during the study period.
  • Clinically significant cardiovascular or cerebrovascular diseases within 6 months before the first study drug administration, including but not limited to: acute myocardial infarction, unstable angina, cerebrovascular accident, clinically significant ventricular arrhythmia, NYHA Class III/IV heart failure, QTcF ≥ 470 ms (female) / 450 ms (male), history of long QT syndrome, LVEF < 50% or severe wall motion abnormality, uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg), or other unsuitable arrhythmias.
  • History of pulmonary disease requiring steroid therapy; active pulmonary tuberculosis within 1 year before the first study drug administration; pulmonary embolism, severe asthma, or severe chronic obstructive pulmonary disease within 3 months; autoimmune or inflammatory diseases involving the lungs; history of prior pneumonectomy on one side.
  • History of gastrointestinal perforation or fistula within 6 months before the first study drug administration, or active gastric/duodenal ulcer, ulcerative colitis, or other gastrointestinal diseases that the investigator considers may cause bleeding or perforation.
  • Uncontrolled active bleeding or known bleeding tendency. If imaging shows tumor invasion of major blood vessels or unclear boundaries, or if the investigator judges that the tumor is highly likely to invade important blood vessels during the subsequent study period causing fatal massive bleeding.
  • History of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolic event within 3 months before the first study drug administration; portal vein tumor thrombus involving both the main trunk and bilateral first-order branches, or involving both the main trunk and superior mesenteric vein, or inferior vena cava tumor thrombus.
  • Presence of any of the following infections: ① Hepatitis B virus; ② Hepatitis C virus; ③ Human immunodeficiency virus; ④ Active Mycobacterium tuberculosis infection; ⑤ Other active infections requiring systemic intravenous anti-infective treatment occurring within 14 days before the first study drug administration; ⑥ Active syphilis infection.
  • Subjects with central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects who have received treatment for brain metastases or have small, asymptomatic, incidental, untreated lesions may be considered for participation, provided that clinical symptoms are stable for at least 4 weeks before study drug administration, no disease progression is confirmed by imaging within 4 weeks before the first dose, all neurological symptoms have completely resolved, no evidence of new or enlarged brain metastases, and radiation, surgery, or steroid therapy was discontinued at least 28 days before the first dose of study treatment. Carcinomatous meningitis and meningeal compression should be excluded regardless of clinical stability.
  • Other malignancies within 3 years before the first dose of study drug, except for cured cancers.
  • Active autoimmune diseases within 6 months before the first dose of study drug. Subjects with hypothyroidism requiring only stable doses of replacement therapy or skin diseases not requiring systemic treatment are eligible.
  • Use of systemic immunosuppressive agents within 2 weeks before the first dose of study drug, excluding: topical glucocorticoids, physiological doses of systemic glucocorticoids, or glucocorticoids used as prophylaxis for hypersensitivity reactions.
  • Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • History of drug abuse or psychiatric illness, or suspected allergy or intolerance to the study drug or any of its components.
  • Other conditions judged by the investigator as unsuitable for participation in the study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: 7MW3711

Participants will receive intravenous (IV) infusion of 7MW3711 as per protocol

Participants will receive intravenous (IV) infusion of 7MW3711 as per protocol

Aktivní komparátor: Docetaxel

Participants will receive intravenous (IV) infusion of Docetaxel as per protocol

Participants will receive intravenous (IV) infusion of Docetaxel as per protocol

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Overall Survival
Časové okno: Up to 34 months

Time from the date of randomization until the date of death from any cause.

Up to 34 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Objective Response Rate per investigator
Časové okno: Up to 34 months

The percentage of subjects who experience a best response of either CR or PR.

Up to 34 months
Progression Free Survival per investigator
Časové okno: Up to 34 months

Time from the date of first randomization to the earliest date of documented disease progression per radiological evidence or death from any cause.

Up to 34 months
Duration of Response per investigator
Časové okno: Up to 34 months

Time from the date of the first complete response (CR) or partial response (PR) to the earliest date of disease progression or death from any cause.

Up to 34 months
Disease Control Rate per investigator
Časové okno: Up to 34 months

The percentage of subjects who experience a best response of CR, PR or stable disease (SD).

Up to 34 months
Time to response per investigator
Časové okno: Up to 34 months

Time from the date of randomization to the date of CR or PR.

Up to 34 months
Incidence of adverse events
Časové okno: Up to 34 months

Adverse events will be assessed by investigator(s) according to NCI-CTCAE v6.0

Up to 34 months
SAE(Serious adverse event)
Časové okno: Up to 34 months

Adverse events will be assessed by investigator(s) according to NCI-CTCAE v6.0

Up to 34 months
Immunogenicity of 7MW3711
Časové okno: Up to 34 months

Incidence of anti-7MW3711 anti-drug antibodies (ADAs) and/or neutralizing antibodies (NAbs)

Up to 34 months
Quality of life (QoL) assessed by EORTC QLQ-C30
Časové okno: Up to 34 months

Quality of life (QoL) assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 consists of functional scales, symptom scales, and a global health status scale. All scores are linearly transformed to a 0 to 100 scale. For functional scales and global health status, higher scores indicate a better outcome (better functioning/quality of life). For symptom scales, higher scores indicate a worse outcome (more severe symptoms).

Up to 34 months
Quality of life (QoL) assessed by EQ-5D-5L
Časové okno: Up to 34 months

Quality of life (QoL) assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L consists of a descriptive system (which can be converted into a utility index score) and a visual analogue scale (EQ VAS). The utility index score typically ranges from 0 to 1, where 1 represents full health, 0 represents death, and higher scores indicate a better outcome. The EQ VAS ranges from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state; higher scores indicate a better outcome.

Up to 34 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. října 2026

Primární dokončení (Odhadovaný)

1. března 2029

Dokončení studie (Odhadovaný)

1. prosince 2029

Termíny zápisu do studia

První předloženo

4. září 2026

První předloženo, které splnilo kritéria kontroly kvality

15. září 2026

První zveřejněno (Aktuální)

21. září 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

21. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

15. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 7MW3711-CP301

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit